Analysts Offer Insights on Healthcare Companies: Xenon (XENE), SELLAS Life Sciences Group (SLS) and Outset Medical (OM)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Xenon (XENE – Research Report), SELLAS Life Sciences Group (SLS – Research Report) and Outset Medical (OM – Research Report).

Xenon (XENE)

In a report released today, Jason Gerberry from Bank of America Securities reiterated a Buy rating on Xenon, with a price target of $52.00. The company’s shares closed last Thursday at $34.72.

According to TipRanks.com, Gerberry is a 1-star analyst with an average return of -0.7% and a 42.8% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Bausch Health Companies, and Tarsus Pharmaceuticals.

Xenon has an analyst consensus of Strong Buy, with a price target consensus of $53.33.

See today’s best-performing stocks on TipRanks >>

SELLAS Life Sciences Group (SLS)

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on SELLAS Life Sciences Group, with a price target of $4.00. The company’s shares closed last Thursday at $1.08, close to its 52-week low of $1.03.

According to TipRanks.com, McCarthy is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -30.2% and a 18.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Brainstorm Cell Therapeutics, and Blue Water Vaccines, Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for SELLAS Life Sciences Group with a $4.00 average price target.

Outset Medical (OM)

In a report released today, Travis Steed from Bank of America Securities downgraded Outset Medical to Sell, with a price target of $3.00. The company’s shares closed last Thursday at $6.77, close to its 52-week low of $6.70.

According to TipRanks.com, Steed is a 4-star analyst with an average return of 5.6% and a 48.5% success rate. Steed covers the Healthcare sector, focusing on stocks such as Inspire Medical Systems, Zimmer Biomet Holdings, and Baxter International.

Outset Medical has an analyst consensus of Hold, with a price target consensus of $10.80.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on XENE:

• Xenon: XEN1101 Phase 2b ‘X-TOLE’ Clinical trial results published
• Xenon Pharmaceuticals Announces Publication of Results from XEN1101 Phase 2b “X-TOLE” Clinical Trial in Peer-Reviewed Journal Article in JAMA Neurology
• Xenon Pharmaceuticals to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
• Xenon Pharmaceuticals added to Q4 2023 Tactical Ideas List at Wells Fargo
• Xenon Pharmaceuticals to Present at TD Cowen’s 3rd Annual Novel Mechanisms in Neuropsychiatry Summit